Novelix Pharmaceuticals Ltd, formerly Trimurthi Limited, is an India-based company, which is engaged in the business of trading pharmaceuticals and related products and is in the business of trading shares and securities. The Company's segments include Pharma Business, Investment is Shares, Trading in shares, Foods, and Finance.

Employees

Sector

Investment Banking & Brokerage Services

More about the company

Quotes

Date	Price	Change	Volume
26-07-29	₹69.00	-3.46%	4,379
26-07-28	₹71.47	-2.63%	1,864
26-07-27	₹73.40	+4.87%	9,877
26-07-24	₹69.99	-0.93%	277
26-07-23	₹70.65	-1.56%	2,017

Delayed Quote Bombay S.E.

More quotes

Income Statement and Estimates

More financial data

Market Closed - Bombay S.E. Other stock markets 06:01:00 2026-07-29 EDT			5-day change	1st Jan Change
69.00 ^INR	-3.46%		-3.86%	+10.19%

07-08	Novelix Pharmaceuticals Limited announced that it has received INR 68.4 million in funding	CI
06-03	Novelix Pharmaceuticals Limited announced that it expects to receive INR 68.4 million in funding	CI

Market Cap	1.11B 11.61M 10.2M 9.52M 8.74M 16.36M 16.76M 113M 44.16M 550M 43.59M 42.64M 1.9B	P/E 2024	1,719x	P/E 2025	296x
Enterprise Value	1.11B 11.54M 10.14M 9.46M 8.69M 16.26M 16.66M 112M 43.89M 547M 43.32M 42.38M 1.89B	EV / Sales 2024	2.32x	EV / Sales 2025	0.84x
Free-Float	24.95%	Yield 2024 *	-	Yield 2025	-

07-08	Novelix Pharmaceuticals Limited announced that it has received INR 68.4 million in funding	CI
06-03	Novelix Pharmaceuticals Limited announced that it expects to receive INR 68.4 million in funding	CI
05-29	Novelix Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2026	CI
03-30	Novelix Pharmaceuticals Limited Announces Resignation of Jivamohan Divakar Valluri as Non-Executive Director and Changes in Committee Composition, Effective March 30, 2026	CI
02-12	Novelix Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI
02-11	Novelix Pharmaceuticals Limited announced that it has received INR 139.2 million in funding	CI
01-10	Novelix Pharmaceuticals Limited Confirms Appointment of Sridevi Belide as Non-Executive Non-Independent Director	CI
12-10	Novelix Pharmaceuticals Limited announced that it expects to receive INR 150 million in funding	CI
11-13	Novelix Pharmaceuticals Limited Announces Board and Committee Changes, Effective 13 November, 2025	CI
25-10-23	Novelix Pharmaceuticals Limited Appoints Sridevi Belide as an Additional Director (Non-Executive Non-Independent), Effective October 23, 2025	CI
25-10-22	Novelix Pharmaceuticals Limited announced that it expects to receive INR 33.22 million in funding from Srinidhi Fine-Chemicals LLP	CI
25-10-17	Novelix Pharmaceuticals signs agreement with GMBU E.V., Halle for astaxanthin	RE
25-10-16	Novelix Pharmaceuticals collaborates with GMBU E.V., Halle (Saale), Germany	RE

1 day	-3.46%
1 week	-3.86%
Current month	-10.21%
1 month	-11.38%
3 months	+23.32%
6 months	+13.58%
Current year	+10.19%

Novelix Pharmaceuticals Limited Stock

Stocks

TRIMURTHI6

INE314I01036

Investment Banking & Brokerage Services

Valuation: Novelix Pharmaceuticals Limited

Chart: Novelix Pharmaceuticals Limited

Latest news : Novelix Pharmaceuticals Limited

Quotes and Performance

Course Extremes

Managers and Directors: Novelix Pharmaceuticals Limited

Other Investment Banking & Brokerage Services

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	66.5	77
1 month	63.19	80.65
Current year	49.01	92
1 year	38	92
3 years	8	92
5 years	5.38	92
10 years	1.85	92

Manager	Title	Age	Since
Bhoomika Choudhary DFI	Director of Finance/CFO	-	2025-02-11
Nishita Kalantri CMP	Compliance Officer	-	2019-03-31

Director	Title	Age	Since
Venkateshwarlu Pulluru BRD	Director/Board Member	-	2024-09-01
Janardhan Das Kabra BRD	Director/Board Member	-	2024-09-01
Gattu Gnana Prakash BRD	Director/Board Member	-	2024-09-01

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NOVELIX PHARMACEUTICALS LIMITED	-3.46%	-3.86%	+57.00%	+627.85%	15.77M
MORGAN STANLEY	-3.99%	-7.03%	+41.49%	+121.83%	333B
THE GOLDMAN SACHS GROUP, INC.	-5.09%	-10.69%	+33.99%	+177.65%	317B
CITIGROUP INC.	-4.03%	-3.87%	+34.56%	+168.15%	222B
CHARLES SCHWAB	-1.42%	+3.64%	+6.70%	+58.38%	184B
CITIC SECURITIES COMPANY LIMITED	+1.46%	+0.71%	-4.84%	+20.41%	59.74B
NOMURA HOLDINGS, INC.	-6.45%	-9.45%	+46.30%	+150.81%	28.05B
LPL FINANCIAL HOLDINGS INC.	-1.35%	+3.18%	-13.54%	+48.90%	27.39B
CSC FINANCIAL CO., LTD.	-2.10%	-6.27%	-11.13%	+26.60%	26.29B
YUANTA FINANCIAL HOLDING CO., LTD.	-2.05%	-1.43%	+103.71%	+171.83%	26.15B
Average	-2.85%	-0.62%	+29.42%	+157.24%	122.36B
Weighted average by Cap.	-3.54%	-2.37%	+29.86%	+128.25%

	2024	2025
Net sales	44.95M 469K 412K 385K 353K 661K 678K 4.56M 1.78M 22.24M 1.76M 1.72M 76.89M	307M 3.21M 2.82M 2.63M 2.42M 4.52M 4.63M 31.21M 12.2M 152M 12.05M 11.79M 526M
Net income	104K 1.09K 955.17 891.58 818.24 1.53K 1.57K 10.57K 4.13K 51.52K 4.08K 3.99K 178K	845K 8.82K 7.75K 7.24K 6.64K 12.43K 12.74K 85.82K 33.56K 418K 33.13K 32.41K 1.45M
Net Debt	-34.91M -364K -320K -299K -274K -514K -526K -3.54M -1.39M -17.27M -1.37M -1.34M -59.72M	-6.79M -70.85K -62.26K -58.11K -53.33K -99.83K -102K -689K -269K -3.36M -266K -260K -11.61M